These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 1354468)
1. FDA's policy statement for the development of new stereoisomeric drugs. Chirality; 1992; 4(5):338-40. PubMed ID: 1354468 [No Abstract] [Full Text] [Related]
2. FDA reform: new Senate bill. Food and Drug Administration. James JS AIDS Treat News; 1995 Nov; (no 235):7-8. PubMed ID: 11363048 [TBL] [Abstract][Full Text] [Related]
4. FDA reform in Congress: FDA's concerns. Food and Drug Administration. James JS AIDS Treat News; 1996 Apr; (no 245):5-7. PubMed ID: 11363624 [TBL] [Abstract][Full Text] [Related]
5. The FDA's response to AIDS: paradigm shift in new drug policy? Podraza R Food Drug Law J; 1993; 48(3):351-75. PubMed ID: 11653267 [No Abstract] [Full Text] [Related]
6. FDA's classification of new drugs. Schneiweiss F N Engl J Med; 1980 Jun; 302(24):1368-9. PubMed ID: 7374693 [No Abstract] [Full Text] [Related]
7. Additions to FDA's drug use policy expected. J Am Vet Med Assoc; 1992 Aug; 201(4):533. PubMed ID: 1517124 [No Abstract] [Full Text] [Related]
8. FDA'S food ingredient approval process: Safety assurance based on scientific assessment. Rulis AM; Levitt JA Regul Toxicol Pharmacol; 2009 Feb; 53(1):20-31. PubMed ID: 18983884 [TBL] [Abstract][Full Text] [Related]
9. Promoting, improving and accelerating the drug development and approval processes. Graul AI Drug News Perspect; 2008; 21(1):36-43. PubMed ID: 18301808 [TBL] [Abstract][Full Text] [Related]
10. FDA's role in making exclusivity determinations. Dickinson EH Food Drug Law J; 1999; 54(2):195-203. PubMed ID: 11758573 [No Abstract] [Full Text] [Related]
11. Linking a policy on nonformulary drugs to the FDA's therapeutic-potential classification system. Poirier TI; Vorbach M; Bache T Am J Hosp Pharm; 1994 Sep; 51(18):2277-8. PubMed ID: 7801989 [No Abstract] [Full Text] [Related]
12. Comments on the proposed change in FDA's trade secrets policy. Hansen RW Am J Pharm Sci Support Public Health; 1977; 149(5):133-7. PubMed ID: 580696 [No Abstract] [Full Text] [Related]
13. Second thoughts: do the FDA's responses to a fatal drug trial and the AIDS activist community's doubts about early access to drugs hint at a shift in basic FDA policy? Lovell MC Food Drug Law J; 1996; 51(2):273-94. PubMed ID: 11820202 [No Abstract] [Full Text] [Related]
14. FDA policy and regulation of stereoisomers: paradigm shift and the future of safer, more effective drugs. Strong M Food Drug Law J; 1999; 54(3):463-87. PubMed ID: 11797710 [No Abstract] [Full Text] [Related]
15. FDA/CVM's Compliance Policy Guide on compounding of drugs. J Am Vet Med Assoc; 1996 Dec; 209(12):2025-9. PubMed ID: 8960175 [TBL] [Abstract][Full Text] [Related]
16. Understanding the FDA's guarded system for classifying new drugs. Schneiweiss F Hosp Pharm; 1979 May; 14(5):262-4, 266, 268 passim. PubMed ID: 10316828 [No Abstract] [Full Text] [Related]
17. Drug industry trying to change FDA's slow but sure policy. Demkovich LE Natl J (Wash); 1979 Jul; 11(29):1211-5. PubMed ID: 10242491 [No Abstract] [Full Text] [Related]
18. FDA's perspective on women and drugs. Danello MA NIDA Res Monogr; 1986; 65():9-13. PubMed ID: 3090447 [No Abstract] [Full Text] [Related]
19. The FDA's policy on the regulation of computerized medical devices. Furfine CS MD Comput; 1992; 9(2):97-100. PubMed ID: 1573995 [No Abstract] [Full Text] [Related]
20. The FDA's drug review process: ensuring drugs are safe and effective. Meadows M FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298 [No Abstract] [Full Text] [Related] [Next] [New Search]